Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Oric Pharmaceuticals, Inc.

NASDAQ: ORIC · Life Sciences · 5 alerts · CIK 1796280

Share price
$7.52Close, Nov 16
Market cap
$782M
Shares outstanding
103.93MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Oric Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:30 PM ET 10-Q
Financial Results

Oric Pharmaceuticals Q3 2026 Results: Net Loss of $48.1M, Loss Widens

For the nine months ended September 30, 2026, ORIC Pharmaceuticals reported a net loss of $125.3 million, an increase from the $99.0 million loss in the prior year period, primarily driven by higher research and development expenses. As of September 30, 2026, the company maintained a strong liquidity position with $345.4 million in cash, cash equivalents, and investments.

Key figure
Net loss $48.1M
4:29 PM ET 8-K
Financial Results

Oric Pharmaceuticals Financial Results

ORIC Pharmaceuticals reported third quarter 2026 financial results and provided updates on its late-stage oncology portfolio, including the initiation of the Himalayas-1 Phase 3 trial for rinzimetostat in prostate cancer. The company ended the quarter with $345 million in cash and investments, which is expected to fund operations into the second half of 2028.

“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC.”

Jacob M. Chacko, M.D., president and chief executive officer

“With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer.”

Jacob M. Chacko, M.D., president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.